Ultrasound Treatment and PolyICLC Injection for Advanced Melanoma Patients
Tests focused ultrasound and an injected drug in adults with advanced melanoma.
Key facts
- Who runs it
- University of Virginia
- Where
- Charlottesville, United StatesSee the site
- Trial code
- Registry title
- FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 11 people, planned
- Started
- 27 Sept 2024
- Planned end
- Aug 2026
- Type of study
- Interventional
- Treatments tested
- Echopulse or Echopulse HD
- PolyICLC
- Record updated
- 20 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced melanoma who are getting checkpoint blockade immunotherapy and plan to have surgery. A tumor must be reachable by ultrasound and by injection.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced melanoma planned for surgical removal. The tumor to be treated must show on ultrasound, be about 1 cm (0.4 in) or more across, and be 5 mm to 23 mm from the skin surface.
- Earlier treatment
- Must be receiving checkpoint blockade (alone or combined) when registered. Some tumors treated earlier with radiation can be used if they grew and a new biopsy was taken. Several recent treatments are not allowed within 4 weeks of study day 1.
Main reasons for not taking part
- Radiation, chemotherapy, interferon, live vaccine, BRAF/MEK targeted therapy or any investigational drug within 4 weeks
- High-dose steroids, with some exceptions
- Pregnant or breastfeeding
- Active infection needing systemic treatment, or New York Heart Association class III or IV heart disease
- HIV or active hepatitis B or C, unless on treatment or viral load not detectable
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Age ≥18 years
- Diagnosis of advanced melanoma planned for surgical resection
- Focused Ultrasound Ablation (FUSA): The targeted lesion(s) must be visible by ultrasound imaging and meet the following criteria; Note: Brain lesions may not be targeted for treatment; Approximately 1 cm (or more) diameter of treatable tumor volume for lesions to be treated with FUSA; The target treatment area needs to be contained within a region at least 5 mm from the skin surface and less than or equal to 23 mm from the skin surface; The target treatment area must be at a safe distance from all critical structures, including but not limited to ribs or other bony structures, vital organs, named blood vessels or nerves; The critical structures, with the exception of the skin, will not be in the pre-focal ultrasound path. This will be considered at enrollment and confirmed immediately prior to treatment; The anterior-posterior dimension of the treatment area by US should be no less than 9 mm
- A subjects target lesion must be amenable to intratumoral injection with polyICLC per the treating clinician's discretion
- Subjects must be receiving checkpoint blockade (either monotherapy or combination therapy) at the time of registration
- Biopsies:; Note: Biopsies may be completed with or without image guidance; Lesions that have been selected for focused ultrasound may have been previously radiated provided:; The tumor site that was previously radiated has progressed; A baseline biopsy of the tumor site is obtained following progression and prior to study entry
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Subjects with known brain metastases may participate if all of the following are true:; There has been no evident growth of any brain metastasis since the most recent treatment; No brain metastasis is > 2 cm in diameter at the time of registration; Neurologic symptoms have returned to baseline,; There is no evidence of new or enlarging brain metastases,; Subjects are not using steroids for at least 7 days prior to registration, except as allowed in Section 5.2. Regardless of dose, however, subjects who are on a steroid taper for management of brain metastases are not eligible until 7 days after completion of that steroid taper
- Ability and willingness to give informed consent
Who cannot take part
- Any of the following medications or treatments are administered to the subject within 4 weeks of study day 1:; Radiation therapy (Note: Stereotactic radiotherapy, such as gamma knife, can be used ≥ 1 week prior to registration); Allergy desensitization injections; High doses of systemic corticosteroids, with the following qualifications and exceptions:; Daily doses of 10 mg or less prednisone (or equivalent) per day administered parenterally or orally are allowed in patients with normal adrenal and pituitary function; In patients with adrenal or pituitary insufficiency replacement steroid doses are allowed; Inhaled steroids (e.g.: Advair®, Flovent®, Azmacort®) are permitted at low doses (less than 500 mcg fluticasone per day, or equivalent) 41,42; Topical and nasal corticosteroids are acceptable; Growth factors (e.g. Procrit®, Aranesp®, Neulasta®); Interleukins (e.g. Proleukin®); Any investigational therapeutic agent; Targeted therapies specific for mutated BRAF or for MEK; Live vaccine; Interferon (e.g. Intron-A®); Cytotoxic chemotherapy for cancer
- Subject has a known addiction to alcohol or drugs and is actively taking those agents, or has recently (within 1 year) taken these agents or has ongoing illicit IV drug use
- Previous treatment with polyICLC within 4 weeks. If a subject was previously treated with intratumoral polyICLC and experienced a significant (grade ≥3) toxicity related to the polyICLC treatment, the tumor that was treated should not be re-treated as part of this protocol
- Subject is known to be HIV positive or has evidence of active Hepatitis B or C virus, unless:; The subject has HIV but has been taking antiretroviral therapy, and agrees to take antiretroviral therapy throughout the study; The subject has active Hepatitis B or C but does not have a detectable viral load
- Active infection requiring systemic therapy
- The presence of Class III or IV heart disease as classified according to the New York Heart Association
- Pregnancy or breastfeeding. Female participants of childbearing potential must have a negative pregnancy test (urinary or serum beta-HCG) obtained within 2 weeks prior to registration. Males and females must agree, in the consent form, to use effective birth control methods during the course of treatment and following treatment in accordance with the labeling guidelines for each approved therapy
- Medical contraindications or potential problems that prevent compliance with the requirements of the protocol in the opinion of the investigator
Where in United States
- University of VirginiaCharlottesville, United StatesContact: Olena GlushakovaTaking people
About the trial
What the trial wants to find out
This study is for adult patients with advanced melanoma who are receiving immunotherapy and who are planning on having surgery for their cancer. All participants in this study will receive an experimental treatment made up of focused ultrasound ablation (FUSA), a non-invasive experimental treatment that uses ultrasound waves to heat and destroy tumor tissue, and an injection in the tumor with an experimental drug that activates the immune system called polyICLC (polyinosinic-polycytidylic acid that is stabilized with carboxymethylcellulose and polylysine). Neither the drug nor the device that are used in this study have been approved by the U.S. Food and Drug Administration (FDA).
The group in the trial
- FUSA + polyICLCTreatment being tested
Focused Ultrasound Ablation plus intratumoral injection of polyICLC
Treatment: Echopulse or Echopulse HD and PolyICLC
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pilot Evaluation of Focused Ultrasound Ablation and Intratumoral PolyICLC in Patients With Regionally Advanced Resectable Melanoma Who Are Receiving Neoadjuvant Immunotherapy
- Plain-language title
- Ultrasound Treatment and PolyICLC Injection for Advanced Melanoma PatientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 November 2025